Patent details

Basic Information

Publication number:

EP2270008

PCT Application Number:

Type:

European Patent Granted for LU

Legal Status:

Lapsed

Application number:

EP101753754

PCT Publication Number:

First applicant's nationality:

Translation Language:

EPO Publication Language:

English

English Title of Invention:

8-heteroaryl-3-alkyl-1,3-dihydro-imidazoÖ4,5-cÜquinolin-2-ones as PI-3 kinases inhibitors

French Title of Invention:

8-Hétéroaryl-3-alkyl-1,3-dihydro-imidazoÖ4,5-cÜquinolin-2-ones comme inhibiteurs des PI-3 kinases

German Title of Invention:

8-Heteroaryl-3-alkyl-1,3-dihydro-imidazoÖ4,5-cÜquinolin-2-on-Verbindungen als PI-3 kinase Hemmer

SPC Number:

Dates

Filing date:

18/05/2006

Grant date:

03/10/2012

EP Publication Date:

03/10/2012

PCT Publication Date:

Claims Translation Received Date:

Translations Received Date (B1 EP Publication):

Translations Received Date (B2 EP Publication):

Translations Received Date (B3 EP Publication):

Publication date:

05/01/2011

EP B1 Publication Date:

03/10/2012

EP B2 Publication Date:

EP B3 Publication Date:

Lapsed date:

18/05/2017

Expiration date:

18/05/2026

Renunciation date:

Revocation date:

Annulment date:

Owner

From:

18/05/2006

 

 

Name:

Novartis AG

Address:

Lichtstrasse 35, 4056 Basel, Switzerland (CH)

Inventor

1

Name:

Garcia-Echeverria Carlos

Address:

Switzerland (CH)

2

Name:

Furet Pascal

Address:

France (FR)

3

Name:

Stauffer Frédéric

Address:

Switzerland (CH)

Priority

Priority Number:

0510390

Priority Date:

20/05/2005

Priority Country:

United Kingdom (GB)

Classification

Main IPC Class:

C07D 471/04;

Annual Fees

Annual Fee Due Date:

Annual Fee Number:

Expected Payer:

Last Annual Fee Payment Date:

09/05/2016

Last Annual Fee Paid Number:

11

Last Annual Fee Paid Amount:

148 Euro

Payer:

MARKS & CLERK LLP

Filing date	Document type	Number of pages